A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Conditions: Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Leiomyosarcoma; Pancreatic Cancer; Sarcom a; CLL Intervention: Drug: CYT-0851 Sponsor: Cyteir Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Leiomyosarcoma | Lymphoma | Myeloma | Oral Cancer | Research | Sarcomas | Study